GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (FRA:F98) » Definitions » PB Ratio

CytoMed Therapeutics (FRA:F98) PB Ratio : 2.74 (As of May. 30, 2024)


View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-30), CytoMed Therapeutics's share price is €1.84. CytoMed Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was €0.67. Hence, CytoMed Therapeutics's PB Ratio of today is 2.74.

The historical rank and industry rank for CytoMed Therapeutics's PB Ratio or its related term are showing as below:

FRA:F98' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 104
Current: 2.82

During the past 4 years, CytoMed Therapeutics's highest PB Ratio was 104.00. The lowest was 0.00. And the median was 0.00.

FRA:F98's PB Ratio is ranked worse than
53.93% of 1309 companies
in the Biotechnology industry
Industry Median: 2.51 vs FRA:F98: 2.82

During the past 12 months, CytoMed Therapeutics's average Book Value Per Share Growth Rate was 1730.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 181.00% per year.

During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of CytoMed Therapeutics was 181.00% per year. The lowest was 181.00% per year. And the median was 181.00% per year.

Back to Basics: PB Ratio


CytoMed Therapeutics PB Ratio Historical Data

The historical data trend for CytoMed Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoMed Therapeutics PB Ratio Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PB Ratio
- - - 4.26

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PB Ratio Get a 7-Day Free Trial - - - - 4.26

Competitive Comparison of CytoMed Therapeutics's PB Ratio

For the Biotechnology subindustry, CytoMed Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoMed Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's PB Ratio falls into.



CytoMed Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

CytoMed Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.84/0.671
=2.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


CytoMed Therapeutics  (FRA:F98) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


CytoMed Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoMed Therapeutics (FRA:F98) Business Description

Traded in Other Exchanges
Address
1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.

CytoMed Therapeutics (FRA:F98) Headlines

No Headlines